COGNIGRAPE is an ingredient developed by BIONAP to improve cognitive performance and prevent neurodegenerative age-related diseases COGNIGRAPE is a standardized powder extract containing high concentrations of active grape substances such as anthocyanins and proanthocyanidins.

WHAT IT DOES

Normal brain ageing is associated with a progressive decline in motor and cognitive functions, often amplified in neurological disorders such as Alzheimer’s disease. The grape polyphenolic compounds contained in COGNIGRAPE can be considered as a natural aid in preventing cognitive deterioration and disorders, mainly due to their antioxidant effect (1-3). COGNIGRAPE supplementation has been clinically proven to improve cognitive function such as attention, language, immediate and delayed memory and, at the same time, it is able to ameliorate the neuropsychological status in healthy older subjects (4).

HOW TO USE

COGNIGRAPE can be used in dietary supplements (capsules, tablets, granules, sachets) and functional foods designed to improve cognitive functions (learning and memory) and to reduce neurodegenerative disorder risks.

BENEFICIAL EFFECTS OF COGNIGRAPE ON NEURONAL AGEING AND BRAIN PERFORMANCE

In recent years, several scientific studies (1-3) have proven that oral administration of grape polyphenols can improve the antioxidant status in the brain and promote basal synaptic transmission in hippocampus, leading to the prevention of free-radical induced neuronal damage and the reduction of amyloid beta-protein aggregation into high-molecular-weight oligomers in brain.

COGNIGRAPE effect in brain function has been recently evaluated in randomized, double-blind, placebo control clinical trial carried out on 111 subjects of healthy older adults (mean age 66.9 ± 5.2 years) (4). Cognitive and neuropsychological status of each subject has been evaluated in treated (250 mg/die) and not treated group at the baseline and after 12 weeks by using Mini-Mental State Examination (MMSE) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Moreover, scale-evaluating tests for anxiety and depression have been used for the assessment of general neuropsychological condition and to exclude any interference of mood on cognitive performance. At the end of the study, a significant increase in MMSE and RBANS score was observed in COGNIGRAPEgroup (figure 1 and figure 2) in comparison with baseline and placebo group, leading to a significant improvement in different items such as attention, language, immediate and delayed memory. In addition and unexpectedly, an interesting improvement of mood status occurred in COGNIGRAPE group that could be related to the better cognitive performance and general neuropsychological subject condition..

Figure 1. MMSE score before and after supplementation with COGNIGRAPE (250 mg/die for 12 weeks) and placebo (*p<0.0001 vs placebo)

Figure 2. RBANS score before and after supplementation with COGNIGRAPE 250 mg/die for 12 weeks) and placebo (*p<0.0001 vs placebo)

Reference

1. Wang J et al., Brain-targeted proanthocyanidin metabolites for Alzheimer’s Disease Treatment. J. Neurosci 32(15): 5144-5150 (2012).

2. Assuҫão M, et al., Red wine antioxidants protects hippocampal neurons against ethanol-induced damage: a biochemical, morphological and behavioral. Neuroscience 146:1581-1592(2007).

3. Wang J, et al., Grape-derived polyphenolics prevent Aß oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer’s Disease. J Neurosci 28(25):6388-6392 (2008).

4. Calapai G, et al., A Randomized, Double-blinded, Clinical Trial on Effects of a Vitis vinifera Extract on Cognitive function in Healthy Older Adults. Front Pharmacol 8:776 (2017).

Copyright © 2016 BIONAP S.r.l
Credit

  • Contrada Fureria Zona Industriale Ovest 95032 Piano Tavola Belpasso (CT) Italy
  • Tel: +39 095 7086560
  • Fax: +39 095 958435
  • info@bionap.com
Home
Company
Quality Research
Applications
Contact Us
Reserved Area
Sign up for our newsletter to receive news and updates.